Monica L. Baskin, PhD, Named Director of VCU Massey Comprehensive Cancer Center
Monica L. Baskin, PhD, will serve as the next Director of VCU Massey Comprehensive Cancer Center, pending approval by the Virginia Commonwealth University Board of Visitors in September. She is also expected to be named the Lipman Chair in Oncology. Dr. Baskin is the first female director of Massey and the first Black woman to be named director of a National Cancer Institute (NCI)-designated cancer center. She will begin in the Director’s role on August 3.
Beth Erickson, MD, FASTRO, Named ASTRO President-Elect
The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ASTRO’s Board of Directors.
Rectal Cancer: AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
Higher tumor cell density in patients with locally advanced rectal cancer receiving irinotecan-intensified neoadjuvant chemoradiotherapy was associated with improved survival outcomes compared with those treated with standard chemoradiotherapy, according to findings from a post-hoc analysis of the phase III ARISTOTLE trial that was published in eBioMedicine.
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E–Positive Differentiated Thyroid Cancer
In a global phase III trial reported in The Lancet Oncology by Gao et al, dabrafenib plus trametinib significantly improved progression-free survival and overall response rate compared with placebo in previously treated patients with locally advanced or metastatic, radioactive iodine–refractory, BRAF V600E–positive differentiated thyroid cancer.
FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC
On July 22, the U.S. Food and Drug Administration (FDA) approved zidesamtinib (Jideytro), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor. The approval comes ahead of the original target action date of September 18, 2026, and follows the FDA's Breakthrough Therapy and Orphan Drug designations.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed/Refractory CLL in the Post-cBTKi SettingMore Top Stories
Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth
Maura L. Gillison, MD, PhD Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything about her as a scientist, a clinician, and a person. She was direct...
Trastuzumab Rezetecan Improves Progression-Free Survival in HER2-Positive Metastatic Breast Cancer
In the phase III HORIZON-Breast01 trial, the HER2-directed antibody-drug conjugate trastuzumab rezetecan significantly improved progression-free survival and showed a distinct safety profile vs pyrotinib plus capecitabine in HER2-positive metastatic breast cancer. The interim analysis, reported by...
ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical questions: when ctDNA testing should (or should not) be used to (1) support cancer diagnosis; (2)...
The Fear of Having Cancer Never Goes Away
There is a strong history of breast cancer in my family, and the fact that I have dense breasts adding to my risk of developing the disease, kept me vigilant about getting a yearly mammogram screening since I turned 32. The test never showed any suspicious lesions over the last nearly 2 decades,...
Fusobacterium Positivity May Predict Relapse Risk, Benefit From Adjuvant Chemotherapy in Colorectal Cancer
When intratumoral Fusobacterium is found in surgical samples of colorectal cancer, the disease is typically more aggressive, with a weaker immune response and limited efficacy for adjuvant chemotherapy, making the cancer more likely to recur, according to findings from the multicenter FUSOMAP...
Electronic Prior Authorization Requirements for Drugs
The Association for Clinical Oncology (ASCO) submitted formal comments (see https://bit.ly/4xYRg1j) to the Centers for Medicare & Medicaid Services (CMS) in response to the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule. If finalized, this rule will require...
New Data on 14- vs 28-Day Venetoclax/Azacitidine in AML
New results from Blood Cancer United’s Beat AML Master Clinical Trial published by Borate et al in the journal Blood provide new information about whether older patients with newly diagnosed acute myeloid leukemia (AML) can receive a shorter schedule of venetoclax when it is given in combination...
